Premium
Phase II study of reduced‐dose craniospinal irradiation and combination chemotherapy for children with newly diagnosed medulloblastoma: A report from the Japanese Pediatric Brain Tumor Consortium
Author(s) -
Okada Keiko,
Soejima Toshinori,
Sakamoto Hiroaki,
Hirato Junko,
Hara Junichi
Publication year - 2020
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.28572
Subject(s) - medicine , medulloblastoma , thiotepa , chemotherapy , vincristine , etoposide , radiation therapy , melphalan , ependymoma , chemotherapy regimen , lomustine , surgery , cyclophosphamide , oncology , pathology
Abstract Background Standard doses of craniospinal irradiation (CSI) are 23.4 Gy for patients with average‐risk and 36 Gy for those with high‐risk medulloblastoma (MB). We investigated whether intensified chemotherapy including intrathecal chemotherapy with simultaneous irradiation is able to reduce CSI dose to 18 Gy. Methods Newly diagnosed average‐risk patients aged 3‐11 years and high‐risk patients aged 3‐18 years were eligible. Patients with Stage M1‐4 disease were classified as high‐risk MB and the others, including M0 patients with >1.5 cm 2 postoperative residual tumor, were classified as average‐risk MB. Patients received chemotherapy consisting of cyclophosphamide, etoposide, cisplatin, and vincristine. Radiotherapy was started concomitantly with the second course of chemotherapy. Radiation doses were 50 Gy to the primary site and 18 Gy to the craniospinal axis. Average‐risk patients received five courses of chemotherapy. High‐risk patients received high‐dose chemotherapy consisting of thiotepa and melphalan following four courses of chemotherapy. All patients received intrathecal methotrexate. Results From 2006 to 2014, 48 patients (35 average and 13 high risk) who met the eligibility/exclusion criteria were enrolled. The 3‐year progression‐free survival (PFS) and 3‐year overall survival (OS) were 90.5% (standard error 5.2%) and 93.9% (4.2%), respectively, for average‐risk patients, and 100% and 100%, respectively, for high‐risk patients. There was no leukoencephalopathy or treatment‐related deaths. Two patients experienced secondary cancer. Conclusions These results suggest that CSI 18 Gy is adequate at least in a proportion of patients with MB treated with intensified chemotherapy including intrathecal methotrexate and simultaneous irradiation, though the results in high‐risk patients were only exploratory.